Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?
Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Door-to-door survey of major neurological disorders (project) in Al Quseir City, Red Sea Governorate, Egypt.
Intrinsic Functional Plasticity of the Thalamocortical System in Minimally Disabled Patients with Relapsing-Remitting Multiple Sclerosis.
Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors.
Ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, inhibits proliferation and differentiation of th17 cells.
Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.
Does cerebrospinal fluid analysis add predictive value to magnetic resonance imaging for long term irreversible disability in patients with early multiple sclerosis?
Inhibition of System Xc- Transporter Attenuates Autoimmune Inflammatory Demyelination.
No association between identified multiple sclerosis non-MHC risk loci and neuromyelitis optica.
[Physiotherapy and neurogenic lower urinary tract dysfunction in multiple sclerosis patients: A randomized controlled trial].
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β
Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity.
The effects of salsa dance on gait and balance in multiple sclerosis (p3.053).
Seminal vesicle fluid ameliorates experimental autoimmune encephalomyelitis by increasing FoxP3(+) regulatory T-cell numbers.
[Antidepressants for treatment of depression in palliative patients : A systematic literature review.]
A proposed roadmap for inpatient neurology quality indicators.
A Long-Term Follow-Up Study Using IPMSSG Criteria in Children With CNS Demyelination.
Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis.
Intramedullary spinal cord metastasis from salivary ductal carcinoma of the parotid gland mimicking transverse myelitis in a patient with radiologically isolated syndrome.
The breakdown of myelin-bound proteins by intra- and extracellular proteases.
Crohn's disease: Is there a place for neurological screening?
Bone marrow-derived macrophages and the CNS: An update on the use of experimental chimeric mouse models and bone marrow transplantation in neurological disorders.
Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA).
Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
Pages
« first
‹ previous
…
561
562
563
564
565
566
567
568
569
…
next ›
last »